cMyc is an attractive target in CTCL since increased expression is observed in the majority of Sézary syndrome patients and in a high proportion of advanced mycosis fungoides [15], [16]. The gene discussed is MYC; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.